Your Health

Ovarian Cancer: Two New Clinical Research Studies Underway

Posted: 9/21/2011

Doctors are investigating new ways to treat ovarian cancer.

(NAPSI)—Doctors around the globe are now recruiting women with recurrent ovarian cancer to participate in two new clinical research studies called TRINOVA-1 and TRINOVA-2.

Although there have been many treatment advances in recent years, up to 90 percent of women treated for advanced ovarian cancer will still experience a relapse of their disease.

“For women with recurrent ovarian cancer, participation in a clinical research study may be an option to consider,” said Bradley Monk, M.D., a principal investigator for the TRINOVA-1 study at Catholic Healthcare West in Phoenix, AZ. “Women participating in these studies may receive an investigational drug which may help researchers find a new way to treat this disease.”

In the United States, ovarian cancer is the fifth leading cause of cancer-related deaths among women.

The purpose of the TRINOVA-1 and TRINOVA-2 studies are to find out whether adding the investigational drug AMG 386 to chemotherapy improves the length of time until the disease progresses compared to treatment with chemotherapy alone.

AMG 386, developed by Amgen, is an investigational new medicine known as an angiogenesis inhibitor. Angiogenesis is the process the body uses to grow new blood vessels, which provide cells and organs with the nutrients and oxygen they need to thrive. Cancer cells also require new blood vessels supplying oxygen and nutrients in order for tumors to grow. Angiogenesis inhibitors are designed to stop the development of these vessels, starving the cancer and slowing or preventing tumor growth.

Participants in the study will receive treatment with either chemotherapy plus AMG 386 or chemotherapy alone. The studies are open to women 18 years of age or older who have been diagnosed with recurrent ovarian cancer and have been previously treated with chemotherapy for management of their disease.

Taking part in a clinical research study is voluntary and a personal decision that should be made after speaking with your doctor. For more information on the two new clinical research trials, visit www.TRINOVAstudies.com.

About The Messenger | Copyright Notice
American River Messenger | Paul V. Scholl, Publisher
7405 Greenback Lane, #129 | Citrus Heights, CA 95610-5603 | Telephone: 916-773-1111 | Fax Line 916-773-2999
Email: publisher@AmericanRiverMessenger.com | Site Designed and Hosted by TheSiteBarn.com
ISSN#: 1948-1969